WT-1
PreclinicalBiologic
WT-1 is one of 14 biologic programs targeting Myeloid Neoplasm. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Myeloid Neoplasm
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 2
CPX-351
Jazz PharmaceuticalsPhase 2
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 1
Jakafi
IncytePhase 1
Cedazuridine
TakedaPhase 3
ASTX030
Taiho Oncology, Inc.Phase 3
Navitoclax
AbbViePhase 1
Leukine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for WT-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details